Impact of long-acting bronchodilators and exposure to inhaled corticosteroids on mortality in COPD: A real-life retrospective cohort study

Lung

Volumn 192, Issue 5, 2014, Pages 649-652

  Manoharan, Arvind ^a   Short, Phillip M ^a   Anderson, William J ^a   Lipworth, Brian J ^a  

^a UNIVERSITY OF DUNDEE   (United Kingdom)

Author keywords

COPD; Inhaled corticosteroids; Long acting beta agonists; Long acting muscarinic antagonists

Indexed keywords

BETA ADRENERGIC RECEPTOR STIMULATING AGENT; CORTICOSTEROID; MUSCARINIC RECEPTOR BLOCKING AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BRONCHODILATING AGENT;

ADULT; AGED; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR MORTALITY; CHRONIC OBSTRUCTIVE LUNG DISEASE; COHORT ANALYSIS; CONTROLLED STUDY; DRUG EXPOSURE; FEMALE; FOLLOW UP; FORCED EXPIRATORY VOLUME; HAZARD RATIO; HUMAN; MAJOR CLINICAL STUDY; MALE; RETROSPECTIVE STUDY; CARDIOVASCULAR DISEASES; CAUSE OF DEATH; COMPARATIVE STUDY; DRUG COMBINATION; DRUG EFFECTS; INHALATIONAL DRUG ADMINISTRATION; LUNG; MIDDLE AGED; MORTALITY; PATHOPHYSIOLOGY; PROPORTIONAL HAZARDS MODEL; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RISK FACTOR; TIME; TREATMENT OUTCOME; UNITED KINGDOM;

ADMINISTRATION, INHALATION; ADRENAL CORTEX HORMONES; ADRENERGIC BETA-ANTAGONISTS; AGED; BRONCHODILATOR AGENTS; CARDIOVASCULAR DISEASES; CAUSE OF DEATH; DRUG THERAPY, COMBINATION; FEMALE; FORCED EXPIRATORY VOLUME; HUMANS; LUNG; MALE; MIDDLE AGED; MUSCARINIC ANTAGONISTS; PROPORTIONAL HAZARDS MODELS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RETROSPECTIVE STUDIES; RISK FACTORS; SCOTLAND; TIME FACTORS; TREATMENT OUTCOME;

EID: 84907591614     PISSN: 03412040     EISSN: 14321750     Source Type: Journal    
DOI: 10.1007/s00408-014-9611-8     Document Type: Article

References (14)

1. National Institute for Health and Clinical Excellence (2010) Chronic obstructive pulmonary disease. NICE guideline (update) consultation. National Institute for Health and Clinical Excellence, London
2. Calverley PMA, Anderson JA, Celli B, Ferguson GT, Jenkins C, Jones PW et al (2007) Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med 356:775-789
3. Tashkin DP, Celli B, Senn S, Burkhart D, Kesten S, Menjoge S et al (2008) A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med 359:1543-1554
4. Salpeter SR, Ormiston TM, Salpeter EE (2004) Cardiovascular effects of beta-agonists in patients with asthma and COPD: a meta-analysis. Chest 125:2309-2321
5. Singh S, Loke YK, Enright P, Furberg CD (2013) Pro-arrhythmic and pro-ischaemic effects of inhaled anticholinergic medications. Thorax 68:114-116
6. Beasley R, Singh S, Loke YK, Enright P, Furberg CD (2012) Call for worldwide withdrawal of tiotropium Respimat mist inhaler. BMJ 345:e7390
7. Hohlfeld J, Sharma A, van Noord J et al (2014) Pharmacokinetics and pharmacodynamics of tiotropium solution and tiotropium powder in chronic obstructive pulmonary disease. J Clin Pharmacol 54(4):405-414. doi: 10.1002/jcph.215
8. Wise RA, Anzueto A, Cotton D, Dahl R, Devins T, Disse B et al (2013) Tiotropium Respimat inhaler and the risk of death in COPD. N Engl J Med 369:1491-1501
9. Short PM, Williamson PA, Elder DH, Lipworth SI, Schembri S, Lipworth BJ (2012) The impact of tiotropium on mortality and exacerbations when added to inhaled corticosteroids and long-acting beta-agonist therapy in COPD. Chest 141:81-86
10. Janson C, Larsson K, Lisspers KH, Ställberg B, Stratelis G, Goike H et al (2013) Pneumonia and pneumonia related mortality in patients with COPD treated with fixed combinations of inhaled corticosteroid and long acting beta2 agonist: observational matched cohort study (PATHOS). BMJ 346:f3306
11. Lee TA, Pickard AS, Au DH, Bartle B, Weiss KB (2008) Risk for death associated with medications for recently diagnosed chronic obstructive pulmonary disease. Ann Intern Med 149:380-390
12. Gershon A, Croxford R, Calzavara A, To T, Stanbrook MB, Upshur R et al (2013) Cardiovascular safety of inhaled long-acting bronchodilators in individuals with chronic obstructive pulmonary disease long-acting bronchodilators in COPD long-acting bronchodilators in COPD. JAMA Intern Med 173:1175-1185
13. Lee TA, Wilke C, Joo M, Stroupe KT, Krishnan JA, Schumock GT et al (2009) Outcomes associated with tiotropium use in patients with chronic obstructive pulmonary disease. Arch Intern Med 169:1403-1410
14. Dong YH, Lin HH, Shau WY, Wu YC, Chang CH, Lai MS (2013) Comparative safety of inhaled medications in patients with chronic obstructive pulmonary disease: systematic review and mixed treatment comparison meta-analysis of randomised controlled trials. Thorax 68:48-56